Gastrointestinal stromal tumor (GIST) · line 1 · Avapritinib monotherapy (GIST advanced/metastatic 1L; PDGFRA D842V)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-AVAPRITINIB-GIST-1L |
| ID | IND-GIST-1L-AVAPRITINIB-PDGFRA-D842V |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-GIST |
| Sources | SRC-NCCN-GIST-2025 |
Notes
Genotype-restricted alternative 1L for the imatinib-resistant PDGFRA D842V subset. Access in Ukraine is via DEC named-patient import or Blueprint Medicines EAP.
Used By
Algorithms
ALGO-GIST-1L- ALGO-GIST-1LALGO-GIST-2L- ALGO-GIST-2L
Indication
IND-GIST-4L-RIPRETINIB- IND-GIST-4L-RIPRETINIB